Pfizer Oncology
Dr. Hariharan, MD,FACP is currently the Global Medical Affairs Lead for the Early Oncology Development pipeline in Pfizer Oncology. He has been at Pfizer Oncology for almost 19 years. During this time, he helped launch sunitinib, axitinib, temsirolimus, and axitinib / PDx combinations in advanced RCC, avelumab in urothelial cancer, and has worked with many of the global experts in GU malignancies on many Phase I, II and III pivotal trials. More recently, he also worked on COVID and cancer and has published numerous articles in peer reviewed journals in over 2 decades. Dr. Hariharan was double Board Certified in Internal Medicine and in Neurology, and fellowship trained in Neuro-Oncology at MSKCC. He was Program Director for the Neurology Residency (currently JFK University Hospital, NJ), and was also Director of the NeuroOncology program. He continues to volunteer as a physician, teach residents and felllows, and see patients as an Attending Physician at NJNSI. He was a faculty speaker at many national and regional ACP annual meetings, and has mentored and trained numerous medical students, residents and fellows over 25 years.
Disclosure information not submitted.